Traduction de «treatment in patients with symptomatic » (Français → Néerlandais) :

A Retrospective Analysis of Surgical Treatment in Patients With Symptomatic Hallux Rigidus: Long-Term Follow-Up The objective of this retrospective study was to analyze the long-term clinical outcomes and patient satisfaction of operative care in patients with symptomatic hallux rigidus.
A Retrospective Analysis of Surgical Treatment in Patients With Symptomatic Hallux Rigidus: Long-Term Follow-Up The objective of this retrospective study was to analyze the long-term clinical outcomes and patient satisfaction of operative care in patients with symptomatic halluxrigidus.

27. Mas JL, Chatellier G, Beyssen B. Carotid angioplasty and stenting with and without cerebral protection: clinical alert from the Endarterectomy Versus Angioplasty in Patients With Symptomatic Severe Carotid Stenosis (EVA-3S) trial.
cerebral protection: clinical alert from the Endarterectomy Versus Angioplasty in Patients With Symptomatic Severe Carotid Stenosis (EVA-3S) trial.

International carotid stenting study (ICSS, called previously CAVATAS-2) recruits symptomatic patients with > 50% stenosis. 40 Surgeons are expected to have performed a minimum of 50 carotid operations with an annual rate of at least 10 cases per year.
International carotid stenting study (ICSS, called previously CAVATAS-2) recruits symptomatic patients with > 50% stenosis.40 Surgeons are expected to have performed a minimum of 50 carotid operations with an annual rate of at least 10 cases per year.

12. Barnett HJ, Taylor DW, Eliasziw M, Fox AJ, Ferguson GG, Haynes RB, et al. Benefit of carotid endarterectomy in patients with symptomatic moderate or severe stenosis.
of carotid endarterectomy in patients with symptomatic moderate or severe stenosis.

36. McKevitt FM, Macdonald S, Venables GS, Cleveland TJ, Gaines PA. Complications following carotid angioplasty and carotid stenting in patients with symptomatic carotid artery disease.
following carotid angioplasty and carotid stenting in patients with symptomatic carotid artery disease.

For primary prevention of stroke, adequate blood pressure reduction, and treatment of hyperlipidemia, use of antithrombotic therapy in patients with atrial fibrillation and of antiplatelet therapy in patients with myocardial infarction are effective and supported by evidence from several
For primary prevention of stroke, adequate blood pressure reduction, and treatment of hyperlipidemia, use of antithrombotic therapy in patients with atrial fibrillation and of antiplatelet therapy in patients with myocardial infarction are effective and supported by evidence from several randomized trials.1 Effective strategies for the secondary prevention of stroke include

Treatment of hyperparathyroidism in patients with end-stage renal disease on haemodialysis and of hypercalcaemia in patients with parathyroid carcinoma
Treatment of hyperparathyroidism in patients with end-stage renal disease on haemodialysis and of hypercalcaemia in patients with parathyroid carcinoma

17. Nelson JC, Kennedy JS, Pollock BG, Laghrissi-Thode F, Narayan M, Nobler MS et al. Treatment of major depression with Nortriptyline and paroxetine in patients with ischemic heart disease.
17. Nelson JC, Kennedy JS, Pollock BG, Laghrissi-Thode F, Narayan M, Nobler MS et al. Treatment of major depression with nortriptyline and paroxetine in patients with ischemic heart disease.

Treatment of patients with EGFRexpressing metastatic colorectal cancer in combination with irinotecan after failure of irinotecancontaining therapy
Treatment of patients with EGFRexpressing metastatic colorectal cancer in combination with irinotecan after failure of irinotecancontaining therapy

The optimal scenario for informing the patient with regard to decisions related to reimbursement of products linked to a specific treatment is similar to the previous one but ( Figure 8) presents a higher number of respondents choosing “inside the organs” and “at each step”.
The optimal scenario for informing the patient with regard to decisions related to reimbursement of products linked to a specific treatment is similar to the previous one but (Figure 8) presents a higher number of respondents choosing “inside the organs” and “at each step”. Only 26% would choose to inform the patient outside the existing organs, and with a stronger preference on informing after the decision is taken.